In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Menarini: East of Eden

Executive Summary

When Alberto Aleotti began running Menarini in the mid-1960s, drug companies in Italy did not do research, because the country offered no patent protection. He believed patents would be key to the industry's growth, and campaigned for years on the issue. As soon as Italy began issuing patents in 1978, Menarini began doing research. Aleotti expected the work would take time to bear fruit, and so he concentrated on helping foreign partners sell their innovative products in Italy and beyond. Menarini's highly successful co-marketing of Glaxo's Zantac spurred other large firms to seek its help too. They signed deals with no upfront fees, only royalties, and Menarini's revenues and infrastructure grew steadily through the 80s. The company's research efforts advanced in parallel with revenue growth, which slowed with scandal-induced price cuts in the 90s. As yet, the work has yielded little of commercial value-but Aleotti says he expected it would take this long. Marketing remains Menarini's core strength, but changing industry dynamics are making novel products harder to come by. The company considers several of its drug candidates very promising, and is now striving to move them along faster. Industry observers are watching the progress of this exceedingly private firm, which says it will soon announce agreements of great strategic importance.

You may also be interested in...

MedPointe's Private Dilemma

MedPointe was born via the leveraged buy-out of an old, private pharmaceutical company, Carter-Wallace. Accepting financial strictures was part of the deal; the company must remain profitable. This increases the challenge for the "founders," seasoned pharma execs intent on leveraging the infrastructure they overhauled, to created an in-licensing based marketing powerhouse. Beyond competing with bigger pharma marketers, management's challenge remains bringing in new assets affordably.

Chiesi's First Step Into Germany

Buying a foothold in Germany filled an important gap in Chiesi's European expansion strategy. But the privately owned Italian group may have to loosen up its dealmaking style to continue to clinch the deals it needs.

Watch Out Pfizer, Moderna - India’s First mRNA Vaccine Is Here

With India’s first and the world’s third mRNA vaccine, Gennova plans to provide access to its COVID-19 vaccine to those deprived of doses from Pfizer and Moderna. HDT Bio Corp’s suit in the US is not seen impacting marketing plans in India, COO tells Scrip


Related Companies

Related Deals

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts